WO2016002760A1 - B細胞集団の製造方法 - Google Patents
B細胞集団の製造方法 Download PDFInfo
- Publication number
- WO2016002760A1 WO2016002760A1 PCT/JP2015/068789 JP2015068789W WO2016002760A1 WO 2016002760 A1 WO2016002760 A1 WO 2016002760A1 JP 2015068789 W JP2015068789 W JP 2015068789W WO 2016002760 A1 WO2016002760 A1 WO 2016002760A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- day
- cell population
- producing
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 72
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 323
- 101100493654 Mus musculus Bach2 gene Proteins 0.000 claims abstract description 76
- 101150062893 Bach2 gene Proteins 0.000 claims abstract description 74
- 108010046304 B-Cell Activation Factor Receptor Proteins 0.000 claims abstract description 46
- 102000007536 B-Cell Activation Factor Receptor Human genes 0.000 claims abstract description 46
- 238000012258 culturing Methods 0.000 claims abstract description 45
- 101150013553 CD40 gene Proteins 0.000 claims abstract description 44
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims abstract description 44
- 230000014509 gene expression Effects 0.000 claims abstract description 28
- 210000004027 cell Anatomy 0.000 claims description 150
- 108010029697 CD40 Ligand Proteins 0.000 claims description 30
- 102100032937 CD40 ligand Human genes 0.000 claims description 30
- 108090000978 Interleukin-4 Proteins 0.000 claims description 19
- 108010074108 interleukin-21 Proteins 0.000 claims description 19
- 230000009471 action Effects 0.000 claims description 16
- 230000004936 stimulating effect Effects 0.000 claims description 14
- 108010017411 Interleukin-21 Receptors Proteins 0.000 claims description 12
- 102000004527 Interleukin-21 Receptors Human genes 0.000 claims description 12
- 108010002350 Interleukin-2 Proteins 0.000 claims description 11
- 102000005962 receptors Human genes 0.000 claims description 11
- 108020003175 receptors Proteins 0.000 claims description 11
- 239000013603 viral vector Substances 0.000 claims description 11
- 210000005260 human cell Anatomy 0.000 claims description 6
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 claims 1
- 101710181056 Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 abstract description 73
- 108091007433 antigens Proteins 0.000 abstract description 73
- 239000000427 antigen Substances 0.000 abstract description 71
- 238000000034 method Methods 0.000 abstract description 42
- 239000013598 vector Substances 0.000 description 54
- 150000001413 amino acids Chemical group 0.000 description 53
- 108090000623 proteins and genes Proteins 0.000 description 36
- 241000699666 Mus <mouse, genus> Species 0.000 description 22
- 230000035755 proliferation Effects 0.000 description 18
- 239000002609 medium Substances 0.000 description 17
- 102000004388 Interleukin-4 Human genes 0.000 description 16
- 230000001177 retroviral effect Effects 0.000 description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 15
- 230000006870 function Effects 0.000 description 12
- 241000283984 Rodentia Species 0.000 description 10
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 10
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 9
- 230000007774 longterm Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 241000894007 species Species 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241000288906 Primates Species 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 102000016605 B-Cell Activating Factor Human genes 0.000 description 5
- 108010028006 B-Cell Activating Factor Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 108091008875 B cell receptors Proteins 0.000 description 4
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 description 3
- 102000015696 Interleukins Human genes 0.000 description 3
- 108010063738 Interleukins Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- 102100021631 B-cell lymphoma 6 protein Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 2
- 101000608935 Homo sapiens Leukosialin Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 102100039564 Leukosialin Human genes 0.000 description 2
- 101100381525 Mus musculus Bcl6 gene Proteins 0.000 description 2
- 101001010620 Mus musculus Interleukin-21 Proteins 0.000 description 2
- 101001002703 Mus musculus Interleukin-4 Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 2
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
- 101100082060 Xenopus laevis pou5f1.1 gene Proteins 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 210000001280 germinal center Anatomy 0.000 description 2
- 102000055229 human IL4 Human genes 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- -1 polyethylene terephthalate Polymers 0.000 description 2
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 230000024704 B cell apoptotic process Effects 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 101150017888 Bcl2 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 1
- 101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100026846 Cytidine deaminase Human genes 0.000 description 1
- 108010031325 Cytidine deaminase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102100035716 Glycophorin-A Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 1
- 101001074244 Homo sapiens Glycophorin-A Proteins 0.000 description 1
- 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710169972 Menin Proteins 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100381517 Mus musculus Bcl2 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000003163 cell fusion method Methods 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 102000050326 human TNFSF13B Human genes 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0635—B lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to a method for producing a B cell population, a B cell population produced by the method for producing a B cell population described above, and a method for producing a monoclonal antibody using the same.
- Monoclonal antibodies exhibiting high selectivity for specific antigens are expected to be developed as antibody drugs, and in particular, antibody drugs targeting cancer cells are being developed.
- a medicine containing a monoclonal antibody as an active ingredient to human treatment it is most ideal from the viewpoint of avoiding rejection reaction to administer a human antibody with a small amount of foreign antigen. For this reason, many chimeric antibodies and humanized antibodies have been developed.
- chimeric antibodies and humanized antibodies for human therapy use mouse IgG antibodies produced by hybridomas after the immunization of mice with an antigen multiple times and then fusion of spleen and lymph node cells with myeloma cells to form hybridomas. Based on this, it is produced using recombinant technology.
- an immunizing antigen shows individual toxicity, immunization to an individual is difficult.
- a protein antigen that is highly conserved among animal species is used as an antigen, antibodies are hardly produced due to immunological tolerance.
- B cells are cells derived from bone marrow and are immune cells having a B cell receptor (BCR) on the surface, and are cells that produce antibodies.
- B cells arise from hematopoietic stem cells and differentiate into B cells via pro-B cells and pre-B cells.
- B cells producing antibodies with high affinity for antigen are known to be selected at the germinal center, but the mechanism of this selection has not been fully elucidated. If B cells that produce antibodies with high affinity for a specific antigen can be artificially grown and concentrated, monoclonal antibodies with high affinity for a specific antigen can be produced in a shorter time. .
- the germinal center is a histological structure formed as a result of proliferation of naive B cells not contacted with an antigen in contact with the antigen, and class switching and somatic hypermutation occur in the germinal center B cells. It has been known.
- Non-Patent Document 2 when splenic B cells are cultured together with IL-4 and anti- ⁇ Hc antibody in the presence of fibroblasts in which BAFF and CD40L are coexpressed, most B cells have a germinal center-like phenotype. It is disclosed that about half of them class-switch to IgG1, and subsequently switch IL-4 to IL-21 to increase IgE-positive cells.
- Patent Document 2 discloses a method for producing an antigen-specific B cell population containing IgG-positive B cells specific for a specific antigen, wherein the IgG-positive B cells are treated with CD40, BAFF receptor in the presence of IL-21. And antigen-specific B cells specific to the specific antigen are selected by culturing with the specific antigen while applying stimulation via Fas, and antigen-specific including an IgG-positive B cell specific to the specific antigen Such a method of production comprising obtaining a B cell population is described.
- Patent Document 3 discloses a method for stabilizing a B cell line, comprising the steps of obtaining B cells, increasing the expression of BCL-6 in the cells, and maintaining the cells in a replicable environment. Are listed.
- Patent Document 4 discloses a method for affecting the stability of an antibody-producing cell, including a step of directly or indirectly affecting the amount of an expression product of BCL6 and / or Blimp-1 in the antibody-producing cell.
- Patent Document 5 describes a non-human animal characterized in that the expression of the bach2 gene is artificially suppressed, and that IgM or / and an IgM-producing hybridoma can be generated with high frequency using the animal. Is described.
- an object of the present invention is to provide a method for easily producing an antigen-specific B cell population containing IgG-positive B cells specific for a specific antigen. Furthermore, the present invention provides a problem to be solved by providing a B cell population produced by the above-described method for producing a B cell population and a method for producing a monoclonal antibody using the above method for producing a B cell population. To do.
- the present inventors have determined that B cells whose Bach2 gene expression is increased by introducing the Bach2 gene into B cells are treated with CD40 and / or ⁇ ⁇ BAFF receptor. By culturing in the presence of the B cell population, it was found that the B cell population can be cultured for a long time at a high growth rate, and the present invention has been completed.
- a method for producing a B cell population comprising a step of culturing B cells in which expression of a Bach2 gene is elevated in the presence of an action means for CD40 and / or BAFF receptors.
- the method for producing a B cell population according to [1], wherein the B cell in which the expression of the Bach2 gene is increased is a cell obtained by introducing the Bach2 gene into the B cell.
- the Bach2 gene is any one of the following genes (a) to (d): (A) a gene comprising a base sequence encoding the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2; (B) a gene comprising a base sequence encoding an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2, and having a function equivalent to that of the Bach2 gene; (C) a gene comprising a base sequence encoding an amino acid sequence in which one or more amino acids are deleted, inserted, substituted and / or added in the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2, A gene having a function equivalent to that of the Bach2 gene; or (d) hybridizing under stringent conditions with a gene having a base sequence complementary to the base sequence encoding the amino acid sequence shown in SEQ ID NO: 1 and
- [4] The method for producing a B cell population according to [2] or [3], wherein a Bach2 gene is introduced into B cells using a viral vector.
- [5] The method for producing a B cell population according to [4], wherein the viral vector is a retroviral vector, a lentiviral vector, an adenoviral vector, or an adeno-associated viral vector.
- the B cell is a mouse cell, and the specific growth rate on day 9 to day 13 after introducing the Bach2 gene into the B cell is 0.6 (1 / day) or more, [1] to [5 ] The manufacturing method of the B cell population in any one of.
- the B cell is a mouse cell, and after introducing the Bach2 gene into the B cell, the 9th to 17th day, the 9th to 22nd day, the 9th to 27th day, and the 9th to 32nd day
- the B cell is a mouse cell, and any one or more of the 13th to 17th day, the 17th to 22nd day, and the 22nd to 27th day after introducing the Bach2 gene into the B cell
- the specific growth rate is 0.6 (1 / day) or more, and the specific growth rate on any one or more of the 27th to 32nd days and the 32nd to 38th days after introducing the Bach2 gene into B cells
- the B cell is a human cell, and the specific growth rate on day 12 to day 18 after introducing the Bach2 gene into the B cell is 0.1 (1 / day) or more, [1] to [5 ]
- the specific proliferation rate in any one or more of the 12th to 24th day and the 12th to 30th day after introducing the Bach2 gene into the B cell is 0.2 ( 1 / day) or more, The method for producing a B cell population according to [6B].
- the specific proliferation rate at any one or more of the 18th to 24th days and the 24th to 30th days after the introduction of the Bach2 gene into the B cells is 0.15 (1 / Day)
- the action means for CD40 and / or BAFF receptor is one or more of any of a structure presenting CD40L and / or BAFF, a stimulating factor of CD40, or a stimulating factor of BAFF receptor, [1 ]
- a structure presenting CD40L and / or BAFF
- a stimulating factor of CD40 or a stimulating factor of BAFF receptor
- the structure is any one of a carrier, a feeder cell, an extracellular matrix, a living tissue, or an organ.
- the CD40 stimulating factor or BAFF receptor stimulating factor is any one of an anti-CD40 antibody, a secreted CD40L, an anti-BAFF receptor antibody, or a secreted BAFF.
- a method for producing the described B cell population [12] The method for producing a B cell population according to any one of [9] to [11], wherein the concentration of a CD40 stimulating factor contained in a medium for culturing B cells is 10 ng / mL or more. [13] The method for producing a B cell population according to any one of [9] to [12], wherein the concentration of the stimulating factor of the BAFF receptor contained in the medium for culturing B cells is 10 ng / mL or more.
- the step of culturing B cells in which the expression of the Bach2 gene is elevated in the presence of an action means for CD40 and / or BAFF receptor comprises the action means for CD40 and / or BAFF receptor and IL-21 reception
- the step of culturing B cells in which the expression of the Bach2 gene is elevated in the presence of an action means for CD40 and / or BAFF receptor comprises an action means for CD40 and / or BAFF receptor, IL-21 reception
- the B cells Prior to introducing the Bach2 gene into B cells, the B cells are cultured in the presence of means for acting on CD40 and / or BAFF receptors and in the presence of IL-4 or IL-4 and IL-2.
- the production method of [20] or [21], wherein the concentration of IL-2 contained in the medium for culturing B cells is 2.5 U / mL or more.
- the step of culturing B cells in which the expression of the Bach2 gene is elevated in the presence of means for acting on CD40 and / or BAFF receptors is a step of culturing in the absence of stimulation via FAS.
- the B cell population according to [25] wherein the B cell has a Bach2 gene incorporated into a viral vector.
- the B cell is a mouse cell, and the specific growth rate from day 9 to day 13 after introducing the Bach2 gene into the B cell is 0.6 (1 / day) or more, [25] or [26 ] B cell population as described in.
- the B cell is a human cell, and the specific growth rate on day 12 to day 18 after introducing the Bach2 gene into the B cell is 0.1 (1 / day) or more, [25] or [26 ] B cell population as described in.
- a method for producing a monoclonal antibody which uses the B cell population produced by the production method according to any one of [1] to [24].
- an antigen-specific B cell population containing IgG-positive B cells specific for a specific antigen can be easily produced.
- FIG. 1 shows the cumulative increase rate of B cells on the fifth day in long-term culture of mouse B cells using a retroviral vector.
- FIG. 2 shows the specific growth rate of B cells after 9 days in long-term culture of mouse B cells using a retroviral vector.
- FIG. 3 shows the specific growth rate for each period of B cells in long-term culture of mouse B cells using a retroviral vector.
- FIG. 4 shows the cumulative increase rate of B cells on the 6th day in long-term culture of human B cells using a retroviral vector.
- FIG. 5 shows the specific growth rate of B cells after 12 days in long-term culture of human B cells using a retroviral vector.
- FIG. 6 shows the specific growth rate for each period of B cells in long-term culture of human B cells using a retroviral vector.
- the method for producing a B cell population of the present invention is a method comprising a step of culturing B cells in which Bach2 gene expression is elevated in the presence of means for acting on CD40 and / or BAFF receptors.
- B cells with increased expression of the Bach2 gene can be obtained by increasing the expression level or abundance of the Bach2 gene originally possessed by the B cell, or cells obtained by introducing the Bach2 gene into the B cell. Any of the cells can be used.
- Methods for increasing the expression level or abundance of the Bach2 gene originally possessed by the B cell include a method of introducing the Menin gene (Nature Communications, 5: 3555, DOI: 10: 1038.ncomms4555) into the B cell, Lept Examples thereof include a method of inhibiting the nuclear export of Bach2 by adding mycin B (LMB) and localizing it to the nucleus, or a method of adding an inhibitor of ubiquitination and degradation by proteasome of Bach2. It is not limited.
- the Bach2 gene is preferably any of the following genes (a) to (d).
- A a gene comprising a base sequence encoding the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2
- B a gene comprising a base sequence encoding an amino acid sequence having 90% or more sequence identity with the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2, and having a function equivalent to that of the Bach2 gene
- C a gene comprising a base sequence encoding an amino acid sequence in which one or more amino acids are deleted, inserted, substituted and / or added in the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2, A gene having a function equivalent to that of the Bach2 gene; or (d) hybridizing under stringent conditions with a gene having a base sequence complementary to the base sequence encoding the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO:
- amino acid sequence shown in SEQ ID NO: 1 is the amino acid sequence of mouse Bach2, and the amino acid sequence shown in SEQ ID NO: 2 is the amino acid sequence of human Bach2.
- sequence identity with the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2 is preferably 90% or more, more preferably 93% or more, still more preferably 95% or more, and particularly preferably 98% or more.
- sequence identity of amino acid sequences is determined by comparing the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2 with the amino acid sequence to be evaluated, and dividing the number of positions where the amino acid matches in both sequences by the total number of amino acids compared. Further, it is expressed by a value obtained by multiplying by 100.
- having a function equivalent to the Bach2 gene means having a function equivalent to a gene consisting of a base sequence encoding the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2, for example, When introduced into B cells, it means that the same cell proliferating function is exhibited. Also, as one of the functions of the Bach2 gene, the expression product of the Bach2 gene binds to the MARE (Maf-recognition element) upstream of the Blimp1 gene promoter and the IRF binding sequence in the fifth intron, thereby transcription of the Blimp1 gene. It is known to suppress. Having a function equivalent to that of the Bach2 gene may have a function of suppressing transcription of the Blimp1 gene as in the case of the Bach2 gene.
- MARE Micro-recognition element
- amino acid sequence modified by deletion, insertion, substitution and / or addition may include only one type (for example, substitution) of modification or two or more modifications (for example, substitution and substitution). Insertion).
- the amino acid to be substituted is preferably an amino acid having a property similar to that of the amino acid before substitution (cognate amino acid).
- amino acids in the same group of the following groups are regarded as homologous amino acids.
- the plurality of amino acids is, for example, 60, preferably 20, more preferably 15, more preferably 10, still more preferably 5, 4, 3, particularly preferably 2 or less. Of amino acids.
- a gene that hybridizes under stringent conditions with a gene having a base sequence complementary to the base sequence encoding the amino acid sequence shown in SEQ ID NO: 1 and / or SEQ ID NO: 2 is SEQ ID NO: 1 and / or SEQ ID NO: 2.
- Colony hybridization method, plaque hybridization method, Southern hybridization method, etc. under stringent conditions using DNA consisting of a base sequence complementary to the base sequence encoding the amino acid sequence shown in FIG. Means DNA obtained by using
- Hybridization can be performed according to the method described in “Molecular Cloning, A Laboratories manual, second seconds edition (Cold Spring, Harbor Laboratory Press, 1989)” and the like.
- the DNA that hybridizes under stringent conditions is, for example, hybridization at 65 ° C. in the presence of 0.7 to 1.0 M NaCl using a filter on which colony or plaque-derived DNA is immobilized.
- DNA that can be obtained by washing the filter under a condition of 65 ° C. using a 2 ⁇ concentration SSC solution (the composition of the 1 ⁇ concentration SSC solution consists of 150 mM sodium chloride and 15 mM sodium citrate) Can be mentioned. It is preferably washed at 65 ° C.
- hybridization conditions have been described as described above, the hybridization conditions are not particularly limited to these conditions.
- a plurality of factors such as temperature and salt concentration can be considered as factors affecting the stringency of hybridization, and those skilled in the art can realize optimum stringency by appropriately selecting these factors.
- a recombinant vector having the Bach2 gene may be constructed, and this recombinant vector may be introduced into the B cell.
- the vector include a viral vector, a plasmid vector, a liposome vector (for example, a cationic liposome vector) and the like.
- virus vectors include retrovirus vectors (eg, lentivirus vectors such as HIV vectors), adenovirus vectors, adeno-associated virus vectors, herpes virus vectors, Sendai virus vectors, baculovirus vectors, and the like.
- the vector is preferably a viral vector, more preferably a retroviral vector (for example, a lentiviral vector such as an HIV vector), an adenoviral vector or an adeno-associated viral vector, and particularly preferably a retroviral vector (for example, Lentiviral vectors such as HIV vectors).
- a retroviral vector for example, a lentiviral vector such as an HIV vector
- an adenoviral vector or an adeno-associated viral vector and particularly preferably a retroviral vector (for example, Lentiviral vectors such as HIV vectors).
- vectors include sequences that control Bach2 gene expression (eg, promoter sequences, terminator sequences, enhancer sequences) and gene markers for selecting host cells (eg, neomycin resistance gene, kanamycin resistance gene) Etc. may be included.
- sequences that control Bach2 gene expression eg, promoter sequences, terminator sequences, enhancer sequences
- gene markers for selecting host cells eg, neomycin resistance gene, kanamycin resistance gene
- Etc e.g, those conventionally used in the field of genetic engineering can be used.
- a method for introducing a vector containing the Bach2 gene into a B cell for example, in the case of a viral vector, it can be performed by infection, and in the case of a plasmid vector, an electroporation method, a calcium phosphate method, a lipofection method or the like can be mentioned. It is done.
- the level of increase in the expression of the Bach2 gene is not particularly limited as long as the effect of the present invention can be obtained.
- the expression level of the Bach2 gene is preferably 1.5 times or more as compared with the original B cell. More preferably, it is the above.
- the B cell used in the present invention is preferably an IgG positive B cell, that is, a B cell having IgG on its surface.
- IgG-positive B cells can be obtained from the cell population containing B cells based on the presence or absence of IgG antibodies.
- the cell population containing B cells used in the present invention is not particularly limited as long as it is generally derived from peripheral blood cells, bone marrow cells or lymphoid organs such as spleen cells.
- the IgG positive B cell may be a naive B cell that has not yet reacted with an antigen, or a B cell that has been contacted with an antigen.
- “naive B cells” generally refer to mature B cells that have not reacted with the antigen, and correspond to cells that exhibit CXCR5-positive and CD40-positive surface antigens.
- the cell population used in the present invention preferably has IL-21 receptor (IL-21R), CD40, BAFF receptor (BAFF-R), preferably has Fas, and further recognizes an antigen.
- IgG positive B cells those containing possible IgG positive B cells are preferred. As long as the object of the present invention is not hindered, other stages of B cells and various cells in the differentiation stage may be included. From the viewpoint of the efficiency of selection by culture, B cells other than IgG positive B cells, such as IgE positive cells, CD138 positive (plasma) cells, and cells other than B cells, such as T cells, monocytes, and NK cells are removed. It is preferable to do.
- the cell population may be a cell population derived from an organism with an established immune system, such as mammalian primates such as humans and monkeys, ungulates such as pigs, cows and horses. Rodents such as mice, rats, rabbits and the like, birds such as chickens and quails are included.
- the origin of this cell population is preferably rodents and primates, and examples thereof include mice and humans.
- a condition for preparing a normal B cell population may be applied as it is.
- it is not limited to a cell population derived from a living body, and may be an established B cell line.
- the culture of the cell population containing B cells can be performed under normal culture conditions using a medium usually used for B cell culture.
- a medium usually used for B cell culture examples include Dulbecco's modified Eagle medium (DMEM) and RPMI 1640.
- DMEM Dulbecco's modified Eagle medium
- RPMI 1640 a medium usually used for B cell culture.
- the culture conditions such as the culture temperature
- the culture conditions used for general B cells can be applied as they are, for example, a condition of 37 ° C. and 5% CO 2 .
- the seeding density of the cell population in the medium varies depending on the origin of the cell population, the state of the cells prepared from the tissue, and the number of culture days performed in the same culture system, but generally 1 ⁇ 10 2 to 1 ⁇ 10 7 cells / cm 2 , preferably 1 ⁇ 10 3 to 1 ⁇ 10 7 cells / cm 2 , and human B cells, in particular, have a higher proliferation rate when they are cultured at a high density. It may be 4 to 1 ⁇ 10 7 pieces / cm 2 . Within this range, it is possible to prevent a hyperproliferative state after culturing for about 4 days.
- B cells used in the present invention When B cells used in the present invention generate intracellular signals by stimulation via CD40, BAFF receptor in the presence of IL-21, IL-21 receptor (IL-21R), CD40, And a BAFF receptor (BAFF-R). Stimulation of these molecules is not limited as long as these molecules are recognized from the outside and an intracellular signal is generated inside an IgG positive B cell having CD40 and BAFF receptors.
- the action means for CD40 and / or BAFF receptor includes one or more of CD40 ligand (CD40L) and / or a structure presenting BAFF, CD40 stimulating factor, or BAFF receptor stimulating factor. Is mentioned.
- CD40 stimulating factors include anti-CD40 antibodies and secretory CD40L.
- CD40L is a ligand for CD40, and the amino acid sequence of CD40L is known (for example, Nature, Vol.357, pp.80-82 (1992) and EMBO J., Vol.11, pp.4313- 4321 (1992)).
- the CD40L sequence may be conserved to such an extent that the binding ability of the active domain involved in the receptor binding ability is not lost.
- the amino acid sequence homology of 80% or more of the active domain may be present.
- Such CD40L may be isolated from cells that naturally express, or may be synthesized based on a known amino acid sequence.
- CD40L should just be a form which can give the signal corresponding to presence of CD40L with respect to B cell in a culture system, and may be a free type or a membrane bound type.
- the CD40 stimulating factor such as free CD40L may be present in the culture system at a concentration at which B cells can maintain proliferation.
- a concentration at which B cells can maintain proliferation for example, 10 ng / ml to Although it is 10 ⁇ g / ml, it can be preferably 50 ng / ml to 10 ⁇ g / ml in consideration of the relative decrease accompanying the proliferation of B cells.
- BAFF receptor stimulating factor examples include anti-BAFF receptor antibodies and secreted BAFF.
- BAFF B-cell activation factor: belonging-to-the-tumor-necrosis-factor-family
- BAFF B-cell activation factor: belonging-to-the-tumor-necrosis-factor-family
- the amino acid sequence of BAFF is already known (for example, J (Exp Med, Vol.189, pp.1747-1756 (1999) and Science, Vol. 285, pp.260-263 (1999) And J Bio Bio Chem, Vol. 274, pp. 15978-15981, (1999)).
- the BAFF sequence need only be conserved to such an extent that the binding ability of the active domain involved in the receptor binding ability is not lost.
- BAFF amino acid sequence homology of the active domain.
- Such BAFF may be isolated from cells that naturally express, or may be synthesized based on a known amino acid sequence. BAFF may be in any form that can give a signal corresponding to the presence of BAFF to IgG-positive B cells in the culture system, and it is membrane-bound even if it is free (ie, secreted). It may be.
- the BAFF receptor stimulating factor such as free BAFF may be present in the culture system at a concentration at which B cells can maintain proliferation.
- concentration 10 ng /
- the concentration can be preferably 50 ng / ml to 10 ⁇ g / ml.
- the step of culturing B cells in which the expression of the Bach2 gene is elevated in the presence of means for acting on CD40 and / or BAFF receptor may be a step of culturing in the absence of stimulation via FAS, or FAS. It may be a step of culturing in the presence of a stimulus via the. Alternatively, B cells cultured in the absence of stimulation via FAS may be subsequently cultured in the presence of stimulation via FAS. In order to selectively enrich B cells, it is preferable to carry out a step of culturing in the presence of a means for acting on CD40 and / or BABA receptor before culturing in the presence of stimulation via FAS.
- Fas ligand is a death factor belonging to the TNF family, that is, a cytokine showing apoptosis-inducing activity, and its amino acid sequence is known (for example, Cell, Vol. 75, pp. 1169-1178 (1993)). )reference.
- the FasL sequence need only be conserved to such an extent that the binding ability of the active domain involved in the receptor binding ability is not lost.
- the amino acid sequence homology is 80% or more of the active domain.
- Such FasL may be isolated from a naturally expressed cell or may be synthesized based on a known amino acid sequence.
- FasL may be in any form that can give a signal corresponding to the presence of Fas to IgG-positive B cells in the culture system, and even if it can generate an intracellular signal, It may be a membrane-bound type. FasL is generally required to be present in the culture system at a concentration capable of inducing apoptosis of B cells. For example, 10 ng / ml to 10 ⁇ g / ml, and a viewpoint of inducing suppression of cell death by antigen stimulation Therefore, the concentration can be preferably 10 ng / ml to 1 ⁇ g / ml.
- CD40L, BAFF and FasL examples include mammalian primates, ungulates, small mammal rodents, birds and the like, preferably rodents and It is derived from mammals, and humans and mice can be exemplified. Moreover, it may be derived from the same species as the cell population to be presented, or may be derived from a different species.
- An antibody or antibody fragment against CD40, BAFF receptor (BAFF-R) or Fas can be obtained according to a method known in the art. There is no particular limitation as long as it is an antibody capable of binding to CD40, BAFF receptor (BAFFR) or Fas. These antibodies or antibody fragments may be in the form presented on the surface of the carrier, or in free or solubilized form that is not immobilized on the antibody surface.
- CD40L, BAFF, or FasL is preferably in the form presented on the surface of the structure from the viewpoint of reliably giving an intracellular signal to B cells in the culture system.
- the structure is preferably a carrier, feeder cell, extracellular matrix, biological tissue or organ.
- Carriers used to present each molecule on the surface include artificial lipid bilayer membranes, plastics such as polystyrene or polyethylene terephthalate, collagen, nylon, nitrocellulose, agar, agarose, sepharose and other polysaccharides, paper, glass, etc. As long as it is usually used for presenting the molecule on the surface, it can be mentioned without particular limitation.
- the shape of the carrier is not particularly limited, and may be any shape such as a sheet shape, a flat plate shape, a spherical shape, a sponge shape, and a fiber shape.
- the structure is preferably a feeder cell from the viewpoint of reliable cell selectivity.
- cells that can be used as feeder cells include fibroblasts, epithelial cells (for example, HeLa cells), fetal kidney cells (for example, HEK293), and follicular dendritic cells. Of these, fibroblasts are preferred from the viewpoints of high growth rate, large cell surface area, and easy removal of feeder cells.
- a feeder cell in which CD40L, BAFF, and optionally FasL is displayed on the cell surface can be prepared by a person skilled in the art using a gene recombination technique based on the known sequences of CD40L, BAFF, and FasL.
- Examples of the origin of feeder cells include mammalian primates, ungulates, small mammal rodents, birds and the like, preferably those derived from rodents and mammals. Yes, examples include mice and humans.
- the feeder cells may be cells derived from the same species as the cell population to be presented, or may be cells derived from different species.
- B cells producing desired IgG may be selected by presenting a specific antigen to IgG-positive B cells.
- the specific antigen means an antigen having affinity for the target antigen-specific IgG-positive B cell, and is appropriately selected according to the purpose.
- the type of antigen is not particularly limited as long as it exhibits antigenicity, and examples thereof include nucleic acids such as DNA and RNA, sugar chains, lipids, amino acids, peptides, proteins, haptens, and low molecular compounds. These substances are only required to be presented in a form that can be recognized by B cells, and may be free or carrier-fixed. From the viewpoint of reliable presentation to B cells, the antigen is preferably in a form immobilized on a carrier.
- the antigen used is known in the art such as a form in which an antigen is added alone, a form in which a known auxiliary molecule is added, and a form in which it binds to an antibody molecule.
- a form that enhances the antigenicity of may be applied.
- a scaffold for displaying the antigen on the carrier surface such as an Fc receptor molecule or protein A or protein G may be further used.
- a protein that binds to a component of the carrier and an antigen protein fusion protein may be used.
- the gene may be introduced into a cell as a carrier in the form of an expression vector for expression.
- an expression vector that can be expressed as a fusion protein of an appropriate signal peptide (not required in the case of a secreted protein) and an appropriate transmembrane region (for example, MHC class I) is transferred to a cell as a carrier. It may be introduced and expressed.
- CD40L, BAFF or FasL, and the antigen are more preferably presented to the feeder cell. It should be noted that CD40L, BAFF, and optionally FasL and an antigen may not necessarily be present on the same feeder cell as long as an intracellular signal can be generated for IgG-positive B cells.
- B cells with increased expression of the Bach2 gene are cultured in the presence of an action means for CD40 and / or BAFF receptor, in the presence of an action means for IL-21 receptor Incubate.
- IL-12 or an anti-IL-21 receptor antibody can be used as a means for acting on the IL-21 receptor.
- IL-21 may be of natural origin or a recombinant obtained by biotechnology. Examples of the origin of IL-21 include mammalian primates, ungulates, small mammal rodents, and birds, as in the cell population described above. Each of these molecules is preferably derived from rodents and mammals, and examples thereof include mice and humans. Further, it may be a molecule derived from the same species as the cell population to be presented, or may be a cell derived from a different species.
- the concentration of IL-21 and / or anti-IL-21 receptor antibody contained in the medium for culturing B cells may be an amount that allows proliferation of IgG-positive B cells having affinity for a specific antigen, In general, it is preferably 1 ng / ml to 1 ⁇ g / ml, more preferably 100 ng / ml to 1 ⁇ g / ml.
- the sorting process may vary depending on conditions such as seeding density and cell type, but generally from the viewpoint of reliable sorting, it is generally at least the second half of the start of the sorting process, and may be 1 to 3 days from the viewpoint of reliable sorting. Although it is preferable that the cell viability is maintained, it may be longer as long as the cell viability is maintained. By culturing for a longer period, antigen-specific IgG-positive B cells having higher affinity Can be obtained.
- the selection step may be repeated while updating the feeder cells. In that case, in order to proliferate IgG positive B cells after each selection step, it is preferable to perform secondary culture described later.
- the concentration and valence of the antigen may be changed (decreased) each time the process is repeated.
- the culture supernatant of the previous step or the antibody produced in the culture supernatant may be added to the culture system when performing the next step. As a result, competition between the B cell receptor and the antibody occurs, and B cells having a higher affinity B cell receptor can be selected.
- B cells in which Bach2 gene expression is elevated are cultured in the presence of a means for acting on CD40 and / or BAFF receptor, in the presence of IL-4 and / or IL-2 May be cultured.
- the culture system does not contain IL-4.
- the cell population containing B cells can be stimulated through stimulation with CD40 and BAFF receptors while giving IL- 4 is preferably obtained by a method including culturing in a primary culturing step in the presence of 4 and a secondary culturing step in the presence of IL-21 (culturing step).
- both primary culture and secondary culture can be performed while applying stimulation via CD40 and BAFF receptors.
- Stimulation via CD40 and BAFF receptors may be carried out using antibodies against these molecules as in the selection step, or CD40L and BAFF may be used.
- a carrier having these antibodies or CD40L and BAFF, such as feeder cells may be used.
- the carrier or feeder cell used in the culturing step may be referred to as a culture carrier or a culture feeder cell, respectively.
- IL-4 used for primary culture may be naturally derived or may be a recombinant obtained by biotechnology.
- concentration of IL-4 is preferably 1 ng / ml to 100 ng / ml, more preferably 5 ng / ml to 100 ng / ml, from the viewpoint of effective proliferation of B cells, more preferably 10 ng / ml to 50 ng / ml. More preferably, it is ml.
- cytokines may be used together with IL-4 depending on the type and origin of the B cell population to be cultured.
- concentration of IL-2 is preferably 1 unit / ml to 1000 units / ml, more preferably 2.5 units / ml to 1000 units / ml, More preferably, it is 2.5 units / ml to 500 units / ml, and particularly preferably 10 units / ml to 100 units / ml.
- the seeding density of the cells at the start of primary culture is not particularly limited, but generally varies depending on the origin of the cell population, the state of the cells prepared from the tissue, and the number of days of culture performed in the same culture system. 2 to 1 ⁇ 10 6 pieces / cm 2 , preferably 1 ⁇ 10 3 to 1 ⁇ 10 6 pieces / cm 2 .
- the primary culture may vary depending on the seeding density, it may generally be 2 to 8 days after the start of the culture from the viewpoint of the proliferation rate of the B cell population, and 3 from the viewpoint of the density of IgG-positive B cells in the cell population.
- the period is preferably from 6 days to 6 days, and more preferably from 3 days to 5 days.
- a predetermined amount of IL-21 may be added to the culture system after the primary culture, and the cells are recovered from the culture system after the primary culture to obtain an IL that does not contain IL-4. You may start by transferring to -21 containing media. From the viewpoint of suppressing the growth rate of IgG-positive B cells in the secondary culture and contamination of IgE-positive B cells in the obtained cell population, the secondary culture is performed with a medium containing IL-21 and not containing IL-4. Most preferably.
- the origins of IL-4 and IL-21 used in the present invention include mammalian primates, ungulates, small mammal rodents, birds and the like, as in the cell population described above.
- Each of these molecules is preferably derived from rodents and mammals, and examples thereof include mice and humans. Further, it may be a molecule derived from the same species as the cell population to be presented, or may be a cell derived from a different species.
- cells other than IgG-positive B cells After completion of the secondary culture, it is preferable to remove cells other than IgG-positive B cells in order to reliably increase the target B cell concentration.
- Examples of cells to be removed include IgE positive B cells, CD138 positive plasma cells, feeder cells (if present), and the like. These cells can be removed by a known technique using an antibody against a specific surface antigen present on the surface.
- cytokines may be used together with IL-21 depending on the type and origin of the B cell population to be cultured.
- concentration of IL-2 is preferably 1 unit / ml to 1000 units / ml, and more preferably 2.5 units / ml to 1000 units / ml. Further, it is more preferably 2.5 units / ml to 500 units / ml, and particularly preferably 10 units / ml to 100 units / ml.
- the method for producing a B cell population of the present invention may be carried out for a period necessary for selecting a target antigen-specific IgG-positive cell, and the number of IgG-positive B cells at the start of the selection process, It can be appropriately changed depending on the type or the state of the feeder cells.
- the selection step may be performed for 1 day to 2 days.
- the primary culture is performed for 3 days to 5 days, and the secondary culture is performed for 2 days to 2 days.
- the selection process may be performed for 1 to 2 days.
- the production method of the present invention may include a growth step for further growing the sorted antigen-specific IgG positive B cells after the sorting step.
- This proliferation step may be performed under culture conditions that allow the antigen-specific IgG-positive B cells to proliferate against the specific antigen selected in the selection step. From the viewpoint of efficient proliferation of the selected IgG-positive B cells. Therefore, it is preferable to culture with CD40L and BAFF in the presence of IL-21.
- the conditions applied in the secondary culture or selection step described above can be applied as they are.
- the above-mentioned matters can be applied as they are to CD40L and BAFF that are preferably used in the proliferation step.
- the proliferation step may be continued for a period according to the number of target IgG-positive B cells in the obtained cell population, and can generally be 1 day or more, preferably 3 days or more, but is included in the culture system. What is necessary is just to adjust suitably according to the growth rate and density of a cell population to be.
- a B cell population produced by the method for producing a B cell population described above is provided.
- the B cell of the present invention preferably has a Bach2 gene incorporated into a viral vector.
- the B cell population of the present invention preferably has a high specific growth rate as described herein below.
- the B cell population of the present invention preferably has a high specific growth rate, but the definition of the specific growth rate by a numerical value defines a preferred embodiment of the B cell population.
- the B cell population of the present invention is produced by the production method (ie, A method of producing a B cell population comprising a step of culturing B cells with increased expression of the Bach2 gene in the presence of a means for acting on CD40 and / or BAFF receptors.
- Proliferation of the B cell population of the present invention can be assessed using specific growth rates.
- m t1 is the number of cells on day t1
- the preferable range of the specific growth rate will be described for the case where the B cell is a mouse cell and the case where the B cell is a human cell.
- the specific growth rate on days 9 to 13 after introducing the Bach2 gene into the B cells is preferably 0.6. (1 / day) or more, more preferably 0.8 (1 / day) or more, and particularly preferably 1.0 (1 / day) or more. Also, after introducing the Bach2 gene into B cells, the 9th to 17th day, the 9th to 22nd day, the 9th to 27th day, the 9th to 32nd day, and the 9th to 38th day
- the specific growth rate in any one or more of the eyes is preferably 0.6 (1 / day) or more.
- the specific growth rate in any one or more of day 9 to day 17, day 9 to day 22, day 9 to day 27 is preferably 0.6 (1 / day) or more, more preferably Is 0.8 (1 / day) or more.
- all the specific growth rates on the 9th to 17th day, the 9th to 22nd day, and the 9th to 27th day are preferably 0.6 (1 / day) or more, more preferably 0.8 (1 / day) or more.
- the specific growth rates on the 9th to 32nd days and on the 9th to 38th days are both 0.6 (1 / day) or more.
- the specific growth rate at any one or more of the 13th to 17th day, the 17th to 22nd day, and the 22nd to 27th day after introducing the Bach2 gene into the B cell is 0.6 (1 / Day) and the specific growth rate of all of the 13th to 17th, 17th to 22nd, and 22nd to 27th days is 0.6 (1 / day) or more. Is preferred.
- the specific growth rate at any one or more of the 27th to 32nd days and the 32nd to 38th days after the introduction of the Bach2 gene into B cells is preferably 0.4 (1 / day) or more.
- the specific growth rates on the 27th to 32nd days and the 32nd to 38th days are preferably 0.4 (1 / day) or more.
- the upper limit of the specific growth rate for mouse B cells is not particularly limited, but is generally 2.3 (1 / day) or less or 1.6 (1 / day) or less.
- the specific growth rate on days 12 to 18 after introducing the Bach2 gene into the B cells is preferably 0.1. (1 / day) or more, more preferably 0.13 (1 / day) or more, and particularly preferably 0.15 (1 / day) or more.
- the specific growth rate in any one or more of the 12th to 24th days and the 12th to 30th days after the introduction of the Bach2 gene into the B cells is preferably 0.1 (1 / day) or more. Yes, more preferably 0.13 (1 / day) or more, and still more preferably 0.15 (1 / day) or more.
- the specific growth rate in the 12th to 30th days after the introduction of the Bach2 gene into B cells is more preferably 0.15 (1 / day) or more, and particularly preferably 0.2 (1 / day) or more. is there.
- the specific growth rate on the 12th to 24th days and on the 12th to 30th days is preferably 0.1 (1 / day) or more, and both are 0.15 (1 / day) or more. Are more preferable, and both are more preferably 0.2 (1 / day) or more.
- the specific growth rate at any one or more of the 18th to 24th days and the 24th to 30th days after the introduction of the Bach2 gene into B cells is preferably 0.15 (1 / day) or more. 0.20 (1 / day) or more is more preferable.
- the specific growth rates on the 18th to 24th days and the 24th to 30th days are both preferably 0.15 (1 / day) or more, more preferably 0.20 (1 / day) or more. More preferred.
- the upper limit of the specific growth rate for the human B cells is not particularly limited, but is generally 1.5 (1 / day) or less, or 1.0 (1 / day) or less.
- the term “antigen-specific IgG-positive B cell population” used for the cells obtained after the above-described sorting step is used in the sense of summarizing the obtained cells. It is not limited to. That is, in addition to being used when referring to a plurality of cells, it is also used when only one cell is present.
- the antigen-specific IgG-positive B cell population of the present invention is a cell population obtained by the production method described above. In this cell population, it is mainly composed of IgG-positive B cells having specificity for the specific antigen used, for example, than a cell population derived from a spleen tissue derived from a living body in primary contact with the same antigen, The density of IgG positive B cells with specificity for antigen is high. Therefore, this antigen-specific IgG-positive B cell population can be suitably used for the production of monoclonal antibodies that require a large amount of IgG-positive B cells having affinity for a specific antigen, cell therapy, and the like. .
- mutations may be introduced into antibody molecules to obtain B cells having various antigen specificities.
- mutation introduction include introduction of mutation into the V region.
- the affinity for the antigen can be further improved.
- a method for introducing a mutation into the V region a known method can be applied. From the viewpoint of certainty of mutation introduction, somatic mutation (SHM) of an antibody gene and antibody constant region region gene
- SHM somatic mutation
- AID activationAinduced cytidine deaminase
- CSR class switch recombination
- a cytokine that enhances the expression of AID may be used.
- mice B cells in a medium containing mouse IL-4 on feeder cells presenting CD40L and BAFF on the cell surface Culturing mouse B cells in a medium containing mouse IL-4 on feeder cells presenting CD40L and BAFF on the cell surface; Infecting the mouse B cells with a retroviral vector containing a Bach2 gene; and culturing the infected mouse B cells in a medium containing mouse IL-21.
- a method is provided.
- a mouse B cell population produced by the method for producing a mouse B cell population described above.
- a method is provided.
- the human B cell population manufactured by the manufacturing method of the above-mentioned human B cell population is provided.
- the method for producing a monoclonal antibody of the present invention includes producing a monoclonal antibody using the cell population obtained by the above-described method for producing a B cell population. Thereby, the monoclonal antibody with respect to a specific antigen can be obtained simply and rapidly.
- a well-known hybridoma production method may be applied to the antigen-specific B cell population.
- a hybridoma is obtained from a cell population containing IgG-positive B cells obtained according to the present invention using a cell fusion method using a well-known method such as myeloma cells.
- the hybridoma producing the antibody to be isolated may be isolated using a limiting dilution method or the like, and the antibody produced by the isolated hybridoma may be recovered.
- a method may be used in which an antibody gene is isolated from the above antigen-specific B cell population and a monoclonal antibody is produced by gene recombination.
- Example 1 Long-term culture of mouse B cells (1) Cell culture Unless otherwise stated, culture of B cell preparations and other cells is RPMI-1640 (10% (v / v) FCS, penicillin / streptomycin. Using 2 mM L-glutamine, 55 nM 2-ME, 10 mM HEPES and 1 mM sodium pyruvate) as a B cell culture medium, the reaction was performed under conditions of 5% (v / v) CO 2 and 37 ° C.
- mice (C57BL / 6, female 8 weeks old) and biotin-anti-mouse CD43 antibody (BD Pharmingen), biotin-anti-mouse CD4 antibody ( Biolegend), biotin-anti-mouse Ter-119 antibody (eBioscience) and biotin-anti-mouse CD11c antibody (eBioscience) were reacted, and CD43, CD4, Ter-119 and CD11c-negative B cells were treated with Streptavidin. -Recovered using Particle Plus-DM and BD IMagnet (BD Bioscience Pharmingen) to obtain mouse B cells.
- biotin-anti-mouse CD43 antibody Biolegend
- biotin-anti-mouse Ter-119 antibody eBioscience
- CD11c antibody eBioscience
- FIG. 1 shows the cumulative increase rate of the number of cells, where the number of each B cell seeded on day 5 is 1.
- Specific proliferation on days 5-9, 9-13, 9-17, 9-22, 9-27, 9-32, and 9-38 for each B cell The speed is shown in FIG.
- the growth rate is shown in FIG.
- the vertical axis of the graphs in FIGS. 2 and 3 indicates (1 / day), which is a unit of specific growth rate. As shown in FIG.
- B cells transformed with mock or Bcl2 have a specific growth rate (1 / day) of about 0.2, whereas Bach2 maintains a specific growth rate of 0.4 or more even on days 32-38. Yes.
- Retrovirus vectors were prepared from these vectors according to a conventional method.
- FIG. 4 shows the cumulative increase rate of the number of cells when the number of seeded B cells on day 6 is 1.
- the specific growth rate on days 6-12, 12-18, 12-24, and 12-30 is shown in FIG.
- the specific growth rate of each B cell on days 6-12, 12-18, 18-24, and 24-30 is shown in FIG.
- the vertical axes of the graphs of FIGS. 5 and 6 indicate (1 / day), which is a unit of specific growth rate.
- Example 3 Long-term culture of human B cells using lentiviral vectors (1) Preparation of lentiviral vectors Multiple cloning of CS2-CMV-MCS (Virology. 2009 Oct 25; 393 (2): 198-209.) Human Bach2 (Oncogene. 2000 Aug 3; 19 (33): 3739-49.) Was subcloned in each site.
- the lentiviral vector was prepared according to the method described in Virology. 2009 Oct 25; 393 (2): 198-209. An empty vector (mock) was obtained that did not subclone human Bach2.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
また、胚中心は、抗原未接触のナイーブB細胞が抗原と接触して増殖した結果形成される組織学的構造であり、胚中心のB細胞にはクラススイッチや体細胞超突然変異が起こることが知られている。例えば、非特許文献2では、BAFFとCD40Lを同時発現させた線維芽細胞の存在下で、IL-4及び抗μHc抗体と共に脾臓B細胞を培養すると、殆どのB細胞が胚中心様の表現型を示すようになり、その約半数はIgG1へクラススイッチすること、及びその後にIL-4をIL-21に切り替えると、IgE陽性細胞が増加することが開示されている。
特許文献3には、B細胞を得る工程、前記細胞中のBCL-6の発現を増加させる工程、および複製できる環境中に前記細胞を維持する工程を含む、B細胞系を安定化させる方法が記載されている。
特許文献5には、bach2遺伝子の発現が人為的に抑制されていることを特徴とする非ヒト動物が記載されており、当該動物を用いてIgMまたは/およびIgM産生ハイブリドーマを高頻度で作成できることが記載されている。
[1] Bach2遺伝子の発現が上昇しているB細胞を、CD40及び/又は BAFF受容体に対する作用手段の存在下において培養する工程を含む、B細胞集団の製造方法。
[2] Bach2遺伝子の発現が上昇しているB細胞が、B細胞にBach2遺伝子を導入することによって得られる細胞である、[1] に記載のB細胞集団の製造方法。
[3] Bach2遺伝子が、下記(a)~(d)の何れかの遺伝子である、[2]に記載のB細胞集団の製造方法。
(a)配列番号1及び/又は配列番号2に示すアミノ酸配列をコードする塩基配列からなる遺伝子;
(b)配列番号1及び/又は配列番号2に示すアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列をコードする塩基配列からなる遺伝子であって、Bach2遺伝子と同等の機能を有する遺伝子;
(c)配列番号1及び/又は配列番号2に示すアミノ酸配列において、1もしくは複数個のアミノ酸が欠失、挿入、置換および/または付加したアミノ酸配列をコードする塩基配列からなる遺伝子であって、Bach2遺伝子と同等の機能を有する遺伝子;又は
(d)配列番号1及び/又は配列番号2に示すアミノ酸配列をコードする塩基配列と相補的な塩基配列を有する遺伝子とストリンジェントな条件下でハイブリダイズする遺伝子であって、Bach2遺伝子と同等の機能を有する遺伝子。
[4] ウイルスベクターを用いてB細胞にBach2遺伝子を導入する、[2]又は[3] に記載のB細胞集団の製造方法。
[5] 前記ウイルスベクターが、レトロウイルスベクター、レンチウイルスベクター、アデノウイルスベクターまたはアデノ随伴ウイルスベクターである、[4]に記載のB細胞集団の製造方法。
[7A] B細胞がマウス細胞であり、B細胞にBach2遺伝子を導入した後9日目~17日目、9日目~22日目、9日目~27日目、9日目~32日目、及び9日目~38日目の何れか1以上における比増殖速度が0.6(1/日)以上である、[6A]に記載のB細胞集団の製造方法。
[8A] B細胞がマウス細胞であり、B細胞にBach2遺伝子を導入した後13日目~17日目、17日目~22日目、及び22日目~27日目の何れか1以上における比増殖速度が0.6(1/日)以上であり、B細胞にBach2遺伝子を導入した後27日目~32日目、及び32日目~38日目の何れか1以上における比増殖速度が0.4(1/日)以上である、[6A]又は[7A]に記載のB細胞集団の製造方法。
[6B] B細胞がヒト細胞であり、B細胞にBach2遺伝子を導入した後12日目~18日目における比増殖速度が0.1(1/日)以上である、[1]から[5]の何れかに記載のB細胞集団の製造方法。
[7B] B細胞がヒト細胞であり、B細胞にBach2遺伝子を導入した後12日目~24日目、及び12日目~30日目の何れか1以上における比増殖速度が0.2(1/日)以上である、[6B]に記載のB細胞集団の製造方法。
[8B] B細胞がヒト細胞であり、B細胞にBach2遺伝子を導入した後18日目~24日目及び24日目~30日目の何れか1以上における比増殖速度が0.15(1/日)以上である、[6B]又は[7B]に記載のB細胞集団の製造方法。
[10] 前記構造物が、担体、フィーダー細胞、細胞外マトリックス、生体組織または臓器の何れかである、[9]に記載のB細胞集団の製造方法。
[11] 前記のCD40の刺激因子又はBAFF受容体の刺激因子が、抗CD40抗体、分泌型CD40L、抗BAFF受容体抗体、又は分泌型BAFFのいずれかである、[9]又は[10]に記載のB細胞集団の製造方法。
[12] B細胞を培養する培地中に含まれるCD40の刺激因子の濃度が10ng/mL以上である、[9]から[11]の何れかに記載のB細胞集団の製造方法。
[13] B細胞を培養する培地中に含まれるBAFF受容体の刺激因子の濃度が10ng/mL以上である、[9]から[12]の何れかに記載のB細胞集団の製造方法。
[15] Bach2遺伝子の発現が上昇しているB細胞を、CD40及び/又は BAFF受容体に対する作用手段の存在下において培養する工程が、CD40及び/又は BAFF受容体に対する作用手段、IL-21受容体に対する作用手段、並びにIL-4及び/又はIL-2の存在下においてB細胞を培養する工程である、[1]から[13]の何れかに記載のB細胞集団の製造方法。
[16] IL-21受容体に対する作用手段が、IL-21及び/又は抗IL-21受容体抗体である、[14]又は[15]に記載のB細胞集団の製造方法。
[17] B細胞を培養する培地中に含まれるIL-21及び/又は抗IL-21受容体抗体の濃度が1 ng/mL以上である、[16]に記載のB細胞集団の製造方法。
[18] B細胞を培養する培地中に含まれるIL-4の濃度が5ng/mL以上である[15]に記載のB細胞集団の製造方法。
[19] B細胞を培養する培地中に含まれるIL-2の濃度が2.5U/mL以上である、[15]又は[18]に記載の製造方法。
[21] B細胞を培養する培地中に含まれるIL-4の濃度が5ng/mL以上である[20]に記載のB細胞集団の製造方法。
[22] B細胞を培養する培地中に含まれるIL-2の濃度が2.5U/mL以上である、[20]又は[21]に記載の製造方法。
[23] Bach2遺伝子の発現が上昇しているB細胞を、CD40及び/又は BAFF受容体に対する作用手段の存在下において培養する工程が、FASを介した刺激の非存在下において培養する工程である、[1]から[22]の何れかに記載のB細胞集団の製造方法。
[24] FASを介した刺激の非存在下において培養した前記B細胞を、FASを介した刺激の存在下において培養する工程をさらに含む、[23]に記載のB細胞集団の製造方法。
[25] [1]から[24]のいずれかに記載の製造方法により製造されるB細胞集団。
[26] B細胞が、ウイルスベクターに組み込まれたBach2遺伝子を有する、[25]に記載のB細胞集団。
[27] B細胞がマウス細胞であり、B細胞にBach2遺伝子を導入した後9日目~13日目における比増殖速度が0.6(1/日)以上である、[25]又は[26]に記載のB細胞集団。
[28] B細胞がヒト細胞であり、B細胞にBach2遺伝子を導入した後12日目~18日目における比増殖速度が0.1(1/日)以上である、[25]又は[26]に記載のB細胞集団。
[29] [1]から[24]のいずれかに記載の製造方法により製造されたB細胞集団を使用する、モノクローナル抗体の製造方法。
本発明のB細胞集団の製造方法は、Bach2遺伝子の発現が上昇しているB細胞を、CD40及び/又は BAFF受容体に対する作用手段の存在下において培養する工程を含む方法である。
(a)配列番号1及び/又は配列番号2に示すアミノ酸配列をコードする塩基配列からなる遺伝子;
(b)配列番号1及び/又は配列番号2に示すアミノ酸配列と90%以上の配列同一性を有するアミノ酸配列をコードする塩基配列からなる遺伝子であって、Bach2遺伝子と同等の機能を有する遺伝子;
(c)配列番号1及び/又は配列番号2に示すアミノ酸配列において、1もしくは複数個のアミノ酸が欠失、挿入、置換および/または付加したアミノ酸配列をコードする塩基配列からなる遺伝子であって、Bach2遺伝子と同等の機能を有する遺伝子;又は
(d)配列番号1及び/又は配列番号2に示すアミノ酸配列をコードする塩基配列と相補的な塩基配列を有する遺伝子とストリンジェントな条件下でハイブリダイズする遺伝子であって、Bach2遺伝子と同等の機能を有する遺伝子。
(第1群:中性非極性アミノ酸)Gly,Ala,Val,Leu,Ile,Met,Cys,Pro,Phe
(第2群:中性極性アミノ酸)Ser,Thr,Gln,Asn,Trp,Tyr
(第3群:酸性アミノ酸)Glu,Asp
(第4群:塩基性アミノ酸)His,Lys,Arg。
IL-21は、天然由来のものであってもよく、生物工学的に得られた組換え体のものであってもよい。IL-21の由来としては、上述した細胞集団と同様に、哺乳動物の霊長類、有蹄類、小型哺乳類の齧歯類、鳥類などが挙げられる。これらの分子はそれぞれ、好ましくは、齧歯類及び哺乳類由来のものであり、例えばマウス、ヒトなどを挙げることができる。また、提示対象となる上記細胞集団と同一の種に由来する分子であってもよく、異なる種に由来する細胞であってもよい。
以下、B細胞がマウス細胞である場合と、B細胞がヒト細胞である場合について、比増殖速度の好ましい範囲について説明する。
本発明によるB細胞集団の製造方法及び上記製造方法から得られたB細胞集団においては、好ましくは、B細胞にBach2遺伝子を導入した後9日目~13日目における比増殖速度が0.6(1/日)以上であり、より好ましくは0.8(1/日)以上であり、特に好ましくは1.0(1/日)以上である。
また、B細胞にBach2遺伝子を導入した後9日目~17日目、9日目~22日目、9日目~27日目、9日目~32日目、及び9日目~38日目の何れか1以上における比増殖速度は、好ましくは0.6(1/日)以上である。9日目~17日目、9日目~22日目、9日目~27日目の何れか1以上における比増殖速度は、好ましくは0.6(1/日)以上であり、より好ましくは0.8(1/日)以上である。好ましくは9日目~17日目、9日目~22日目、9日目~27日目のすべての比増殖速度は、好ましくは0.6(1/日)以上であり、より好ましくは0.8(1/日)以上である。
9日目~32日目及び9日目~38日目の比増殖速度はともに0.6(1/日)以上であることが好ましい。
また、B細胞にBach2遺伝子を導入した後27日目~32日目及び32日目~38日目の何れか1以上における比増殖速度が0.4(1/日)以上であることが好ましく、27日目~32日目及び32日目~38日目の比増殖速度がともに0.4(1/日)以上であることが好ましい。
本発明によるB細胞集団の製造方法及び上記製造方法から得られたB細胞集団においては、好ましくは、B細胞にBach2遺伝子を導入した後12日目~18日目における比増殖速度が0.1(1/日)以上であり、より好ましくは0.13(1/日)以上であり、特に好ましくは0.15(1/日)以上である。
12日目~24日目、及び12日目~30日目の比増殖速度はともに0.1(1/日)以上であることが好ましく、ともに0.15(1/日)以上であることがより好ましく、ともに0.2(1/日)以上であることがさらに好ましい。
CD40L及びBAFFを細胞表面に提示するフィーダー細胞上においてマウスIL-4を含有する培地中においてマウスB細胞を培養する工程;
Bach2遺伝子を含むレトロウイルスベクターを前記マウスB細胞に感染させる工程;及び
前記感染されたマウスB細胞を、マウスIL-21を含有する培地中で培養する工程:を含む、マウスB細胞集団の製造方法が提供される。さらに本発明によれば、上記したマウスB細胞集団の製造方法により製造されるマウスB細胞集団が提供される。
CD40L及びBAFFを細胞表面に提示するフィーダー細胞上においてヒトIL-4及びヒトIL-2を含有する培地中においてヒトB細胞を培養する工程;
Bach2遺伝子を含むレトロウイルスベクターを前記ヒトB細胞に感染させる工程;及び
前記感染されたヒトB細胞を、ヒトIL-21を含有する培地中で培養する工程:を含む、ヒトB細胞集団の製造方法が提供される。さらに本発明によれば、上記したヒトB細胞集団の製造方法により製造されるヒトB細胞集団が提供される。
(1)細胞の培養
B細胞調製物及び他の細胞の培養は、特に断らない限り、RPMI-1640(10%(v/v) FCS、ペニシリン/ストレプトマイシン、2mM L-グルタミン、55nM 2-ME、10mM HEPES及び1mM ピルビン酸ナトリウム添加)をB細胞培養培地として用いて、5%(v/v)CO2、37℃の条件下で行った。
マウス(C57BL/6、メス8週齢)から脾臓細胞を得て、常法により、ビオチン-抗マウスCD43抗体(BD Pharmingen社製)、ビオチン-抗マウスCD4抗体(Biolegend社製)、ビオチン-抗マウスTer-119抗体(eBioscience社製)、ビオチン-抗マウスCD11c抗体(eBioscience社製)を反応させ、CD43、CD4、Ter-119及びCD11c陰性のB細胞を、Streptavidin-Particle Plus-DM、BD IMagnet(BD Bioscience Pharmingen社製)を用いて回収し、マウスB細胞を得た。
pMX-IRES-GFPベクター(Proc Natl Acad Sci U S A, Vol.97, pp.3062-3066 (2000))のマルチクローニングサイトにマウスBcl-6(Oncogene. 1995 Oct 19;11(8):1657-63.)、マウスBach2(Mol Cell Biol. 1996 Nov;16(11):6083-95.)、マウスBcl-2(Cell. 1987 May 22;49(4):455-63.)をそれぞれサブクローニングした。また、何も組み込まないベクターを空ベクター(mock)とした。これらのベクターから定法に従ってそれぞれレトロウイルスベクターを作製した。
CD40L及びBAFFを細胞表面に提示するフィーダー細胞、40LB細胞は、特開2011-92142号公報に記載の細胞を用いた。実験には、直径10cm細胞培養プレート(BD Falcon社製)に、40LB細胞を3×106個播種し、24時間培養して単一層を形成させた後、120Gyのγ線を照射してからフィーダー細胞として使用した。上記(2)で調製したB細胞をフィーダー細胞上に、1.25×104個/mlの細胞密度で播種し、マウスIL-4(10 ng/ml、PEPRO TECH社製)を含有するB細胞培養培地で培養した。培養3日目に上記(3)で調製したレトロウイルスベクターのそれぞれをB細胞に感染させた。
各B細胞について、5~9日目、9~13日目、9~17日目、9~22日目、9~27日目、9~32日目、及び9~38日目の比増殖速度を図2に示す。
また各B細胞について、5~9日目、9~13日目、13~17日目、17~22日目、22~27日目、27~32日目、及び32~33日目の比増殖速度を図3に示す。
図2及び図3のグラフの縦軸は、比増殖速度の単位である(1/日)を示す。
図1に示されるように、mockやBcl2により形質転換したB細胞では、9日目以降ほとんど細胞が増殖しなくなる。また、Bcl6により形質転換したB細胞では、比増殖速度(1/日)は0.2程度であるのに対しBach2では、32-38日目でも0.4以上の比増殖速度を維持している。
(1)レトロウイルスベクターの調製
pMX-IRES-hCD8(Nat Commun. 2011 Sep 6;2:465.)よりNcoI-SalIでhCD8断片を調製し、pMXs-IGベクター(EMBO J. 1999 Sep 1;18(17):4754-65.)のNcoI-SalIにサブクローニングし、pMXs-IRES-hCD8とした。これを空ベクター(mock)とした。pMXs-IRES-hCD8のBamHI-NotI間にコザック配列を含む形で、ヒトBach2(Oncogene. 2000 Aug 3;19(33):3739-49.)をサブクローニングし、pMXs-hBach2-IRES-hCD8とした。これをヒトBach2発現ベクターとした。これらのベクターから定法に従ってそれぞれレトロウイルスベクターを作製した。
健常人のヒト末梢血からFicoll-Paque PLUS(GEヘルスケア株式会社製)を用いてリンパ球を分離した。常法により、ビオチン-抗ヒトCD2抗体(Biolegend社製)、ビオチン-抗ヒトCD235a抗体(eBioscience社製)を反応させ、CD2、CD235陰性の細胞を、Streptavidin-Particle Plus-DM、BD IMagnet(BD Bioscience Pharmingen社製)を用いて回収した。これに常法により、PE/Cy7抗ヒトCD19抗体を反応させ、ARIAII(BD バイオサイエンス社製)でCD19陽性の細胞ソーティングし、ヒトB細胞を得た。
回収したB細胞を、実施例1と同様に準備した40LB上で、ヒトIL-4(50ng/ml、PEPRO TECH社製)、ヒトIL-2(25 unit/ml、PEPRO TECH社製)を含有するB細胞培養培地で培養した。培養4日目に上記(1)で調製したレトロウイルスベクターのそれぞれをB細胞に感染させた。培養6日目に全細胞を、2mMのEDTAと0.5%のBSAを含むPBSを用いてフィーダー細胞ごと剥がし、ピペットでフラッシュして回収した。新たに準備された40LB細胞が播種されたプレートに、ヒトIL-21(10 ng/ml、PEPRO TECH社製)を含有するB細胞培養培地に、回収された細胞集団を、1×105個/ml以下の細胞密度で播種して、培養を行った。
各B細胞の6日目に播種した数を1とした細胞数の累積増加率を図4に示す。
各B細胞について、6~12日目、12~18日目、12~24日目、及び12~30日目の比増殖速度を図5に示す。
また各B細胞について、6~12日目、12~18日目、18~24日目、及び24~30日目の比増殖速度を図6に示す。
図5及び図6のグラフの縦軸は、比増殖速度の単位である(1/日)を示す。
上記方法により、ヒトB細胞を長期培養することができる。
(1)レンチウイルスベクターの調製
CS2-CMV-MCS(Virology. 2009 Oct 25;393(2):198-209.)のマルチクローニングサイトにヒトBach2(Oncogene. 2000 Aug 3;19(33):3739-49.)をそれぞれサブクローニングした。レンチウイルスベクターの調製はVirology. 2009 Oct 25;393(2):198-209.に記載の方法に従った。ヒトBach2をサブクローニングしないものを空ベクター(mock)とした。
健常人のヒト末梢血からLymphoprep Tube(Axis-Shield PoC AS社製)を用いて単核球を分離し、さらにB Cell アイソレーションキットII, ヒト(Miltenyi Biotec社製)を用いてヒトB細胞を得た。
回収したB細胞に、上記(1)で調製したレトロウイルスベクターのそれぞれを、感染させた。感染後、直径10cm細胞培養プレート(BD Falcon社製)に、1.25×104個/mlの細胞密度で播種し、抗CD40抗体(1 μg/ml、Beckman Coulter社製)、分泌型ヒトBAFF(1 μg/ml、PEPRO TECH社製)、ヒトIL-4(50 ng/ml、PEPRO TECH社製)、ヒトIL-2(25 unit/ml、PEPRO TECH社製)を含有するB細胞培養培地で培養した。培養5日目に全細胞を回収し、抗CD40抗体(1 μg/ml、Beckman Coulter社製)、分泌型ヒトBAFF(1 μg/ml、PEPRO TECH社製)、ヒトIL-21(10 ng/ml、PEPRO TECH社製)、ヒトIL-2(25 unit/ml、PEPRO TECH社製)を含有するB細胞培養培地で培養した。
上記方法により、ヒトB細胞を長期培養することができる。
Claims (15)
- Bach2遺伝子の発現が上昇しているB細胞を、CD40及び/又は BAFF受容体に対する作用手段の存在下において培養する工程を含む、B細胞集団の製造方法。
- Bach2遺伝子の発現が上昇しているB細胞が、B細胞にBach2遺伝子を導入することによって得られる細胞である、請求項1に記載のB細胞集団の製造方法。
- ウイルスベクターを用いてB細胞にBach2遺伝子を導入する、請求項2に記載のB細胞集団の製造方法。
- B細胞がマウス細胞であり、B細胞にBach2遺伝子を導入した後9日目~13日目における比増殖速度が0.6(1/日)以上である、請求項1から3の何れか1項に記載のB細胞集団の製造方法。
- B細胞がヒト細胞であり、B細胞にBach2遺伝子を導入した後12日目~18日目における比増殖速度が0.1(1/日)以上である、請求項1から3の何れか1項に記載のB細胞集団の製造方法。
- 前記CD40及び/又はBAFF受容体に対する作用手段が、CD40L及び/又はBAFFを提示した構造物、CD40の刺激因子、又はBAFF受容体の刺激因子の何れかで1以上である、請求項1から5の何れか1項に記載のB細胞集団の製造方法。
- Bach2遺伝子の発現が上昇しているB細胞を、CD40及び/又は BAFF受容体に対する作用手段の存在下において培養する工程が、CD40及び/又は BAFF受容体に対する作用手段及びIL-21受容体に対する作用手段の存在下においてB細胞を培養する工程である、請求項1から6の何れか1項に記載のB細胞集団の製造方法。
- Bach2遺伝子の発現が上昇しているB細胞を、CD40及び/又は BAFF受容体に対する作用手段の存在下において培養する工程が、CD40及び/又は BAFF受容体に対する作用手段、IL-21受容体に対する作用手段、並びにIL-4及び/又はIL-2の存在下においてB細胞を培養する工程である、請求項1から7の何れか1項に記載のB細胞集団の製造方法。
- IL-21受容体に対する作用手段が、IL-21及び/又は抗IL-21受容体抗体である、請求項7又は8に記載のB細胞集団の製造方法。
- B細胞にBach2遺伝子を導入する前に、B細胞を、CD40及び/又は BAFF受容体に対する作用手段の存在下、かつIL-4あるいはIL-4及びIL-2の存在下で培養する、請求項2又は3に記載のB細胞集団の製造方法。
- 請求項1から10のいずれか1項に記載の製造方法により製造されるB細胞集団。
- B細胞が、ウイルスベクターに組み込まれたBach2遺伝子を有する、請求項11に記載のB細胞集団。
- B細胞がマウス細胞であり、B細胞にBach2遺伝子を導入した後9日目~13日目における比増殖速度が0.6(1/日)以上である、請求項11又は12に記載のB細胞集団。
- B細胞がヒト細胞であり、B細胞にBach2遺伝子を導入した後12日目~18日目における比増殖速度が0.1(1/日)以上である、請求項11又は12に記載のB細胞集団。
- 請求項1から10のいずれか1項に記載の製造方法により製造されたB細胞集団を使用する、モノクローナル抗体の製造方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016531384A JP6684211B2 (ja) | 2014-07-02 | 2015-06-30 | B細胞集団の製造方法 |
EP15814202.6A EP3165602B1 (en) | 2014-07-02 | 2015-06-30 | Method for producing b cell population |
US15/322,325 US10428304B2 (en) | 2014-07-02 | 2015-06-30 | Method for producing B cell population |
US16/180,592 US10781423B2 (en) | 2014-07-02 | 2018-11-05 | Method for producing B cell population |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014136631 | 2014-07-02 | ||
JP2014-136631 | 2014-07-02 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/322,325 A-371-Of-International US10428304B2 (en) | 2014-07-02 | 2015-06-30 | Method for producing B cell population |
US16/180,592 Division US10781423B2 (en) | 2014-07-02 | 2018-11-05 | Method for producing B cell population |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016002760A1 true WO2016002760A1 (ja) | 2016-01-07 |
Family
ID=55019292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/068789 WO2016002760A1 (ja) | 2014-07-02 | 2015-06-30 | B細胞集団の製造方法 |
Country Status (4)
Country | Link |
---|---|
US (2) | US10428304B2 (ja) |
EP (1) | EP3165602B1 (ja) |
JP (1) | JP6684211B2 (ja) |
WO (1) | WO2016002760A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018131698A1 (ja) | 2017-01-16 | 2018-07-19 | 株式会社カネカ | B細胞集団の製造方法、及びそれを用いたモノクローナル抗体の製造方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110433A1 (ja) * | 2004-05-17 | 2005-11-24 | Kazuhiko Igarashi | Bach2の発現が人為的に抑制されている非ヒト動物とその利用 |
JP2011092142A (ja) * | 2009-10-30 | 2011-05-12 | Tokyo Univ Of Science | 抗原特異的b細胞集団の製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0763057T3 (da) | 1994-04-28 | 2006-03-27 | Boehringer Ingelheim Pharma | Fremgangsmåde til proliferering og differentiering af B celler og anvendelse deraf |
EP2141228A1 (en) | 2001-12-18 | 2010-01-06 | Cancer Research Technology Limited | Method for the generation of proliferating and differentiating B cell lines |
PT2540820T (pt) | 2005-12-09 | 2018-03-02 | Academisch Medisch Centrum Bij De Univ Van Amsterdam | Meios e métodos para influenciar a establidade de células produtoras de anticorpos |
US8394568B2 (en) * | 2009-11-02 | 2013-03-12 | Xerox Corporation | Synthesis and emulsification of resins |
-
2015
- 2015-06-30 WO PCT/JP2015/068789 patent/WO2016002760A1/ja active Application Filing
- 2015-06-30 US US15/322,325 patent/US10428304B2/en active Active
- 2015-06-30 EP EP15814202.6A patent/EP3165602B1/en active Active
- 2015-06-30 JP JP2016531384A patent/JP6684211B2/ja active Active
-
2018
- 2018-11-05 US US16/180,592 patent/US10781423B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005110433A1 (ja) * | 2004-05-17 | 2005-11-24 | Kazuhiko Igarashi | Bach2の発現が人為的に抑制されている非ヒト動物とその利用 |
JP2011092142A (ja) * | 2009-10-30 | 2011-05-12 | Tokyo Univ Of Science | 抗原特異的b細胞集団の製造方法 |
Non-Patent Citations (4)
Title |
---|
MIURA, Y. ET AL.: "Transcriptional repressor Bach2 promotes B cell receptor-induced proliferation", ANNUAL MEETING OF THE MOLECULAR BIOLOGY SOCIETY OF JAPAN PROGRAM·YOSHISHU (WEB, vol. 34 th, 2011, pages 4P-0422, XP008185847 * |
MOROOKA, M. ET AL.: "The essential role of Bach2 in B- cell receptor-induced proliferation and survival", PROCEEDINGS OF THE JAPANESE SOCIETY FOR IMMUNOLOGY, vol. 42, 18 November 2013 (2013-11-18), pages 161, XP008185782 * |
SASAKI, S. ET AL.: "Cloning and expression of human B cell -specific transcription factor BACH2 mapped to chromosome 6q15", ONCOGENE, vol. 19, no. 33, 2000, pages 3739 - 3749, XP002978355, ISSN: 0950-9232 * |
See also references of EP3165602A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018131698A1 (ja) | 2017-01-16 | 2018-07-19 | 株式会社カネカ | B細胞集団の製造方法、及びそれを用いたモノクローナル抗体の製造方法 |
CN110418838A (zh) * | 2017-01-16 | 2019-11-05 | 株式会社钟化 | B细胞群的制备方法、以及使用了其的单克隆抗体的制备方法 |
JPWO2018131698A1 (ja) * | 2017-01-16 | 2019-11-21 | 株式会社カネカ | B細胞集団の製造方法、及びそれを用いたモノクローナル抗体の製造方法 |
JP7075898B2 (ja) | 2017-01-16 | 2022-05-26 | 株式会社カネカ | B細胞集団の製造方法、及びそれを用いたモノクローナル抗体の製造方法 |
US11578132B2 (en) | 2017-01-16 | 2023-02-14 | Kaneka Corporation | Method for producing B cell population and method for producing monoclonal antibody using same |
CN110418838B (zh) * | 2017-01-16 | 2023-07-28 | 株式会社钟化 | B细胞群的制备方法、以及使用了其的单克隆抗体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
EP3165602A1 (en) | 2017-05-10 |
US20170137782A1 (en) | 2017-05-18 |
EP3165602B1 (en) | 2020-12-09 |
JP6684211B2 (ja) | 2020-04-22 |
US10781423B2 (en) | 2020-09-22 |
JPWO2016002760A1 (ja) | 2017-04-27 |
EP3165602A4 (en) | 2017-11-29 |
US20200255802A1 (en) | 2020-08-13 |
US10428304B2 (en) | 2019-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11530272B2 (en) | Smart car devices, DE car polypeptides, side CARs and uses thereof | |
KR20200088383A (ko) | T-세포 수용체 및 베타 2-마이크로글로불린 발현을 제거하도록 유전자 변형된 불멸화 car-t 세포 | |
JP7039623B2 (ja) | 形質転換されたt細胞を用いてナチュラルキラー細胞を培養する方法 | |
EP3741778A1 (en) | A t cell which expresses an anti-gd2 chimeric antigen receptor | |
KR20180021137A (ko) | 키메라 항원 수용체 (car), 조성물 및 이의 사용 방법 | |
CN112714769A (zh) | Ror-1特异性嵌合抗原受体及其用途 | |
CN110857319B (zh) | 一种分离的t细胞受体、其修饰的细胞、编码核酸及其应用 | |
EP2495312B1 (en) | Method for producing antigen-specific b cell population | |
CN107827989A (zh) | 靶向骨髓瘤bcma抗原的转基因t细胞及其制备方法与应用 | |
CN112533957A (zh) | Muc16特异性嵌合抗原受体及其用途 | |
CN113195712A (zh) | 突变型piggyBac转座酶 | |
TWI817994B (zh) | 基因修飾細胞及其製備方法 | |
CN114127287A (zh) | 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法 | |
WO2022116952A1 (zh) | 靶向cd70的抗原结合蛋白及其应用 | |
US10781423B2 (en) | Method for producing B cell population | |
CN109810197B (zh) | 用于高效扩增nk的人工抗原递呈细胞及其构建方法 | |
WO2023109514A1 (zh) | 膜整合型融合蛋白、含有其的细胞及用途 | |
CN114907485B (zh) | 一种以内源性蛋白质分子替代单结构域抗体的嵌合抗原受体 | |
US20130196380A1 (en) | In vitro process for the preparation of antibodies of the igg type | |
US20230212257A1 (en) | Anti-cd171 chimeric antigen receptors | |
RU2816370C2 (ru) | Устойчивые к ритуксимабу химерные антигенные рецепторы и пути их применения | |
TW202237825A (zh) | 針對同種異體細胞療法的通用嵌合抗原受體表現之免疫細胞 | |
CN117925532A (zh) | 一种car-nk细胞及其制备方法和应用 | |
CN117979977A (zh) | 用于细胞疗法的b细胞扩增方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15814202 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016531384 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15322325 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015814202 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015814202 Country of ref document: EP |